Since November, House leaders John Dingell (D-Mich.) and Bart Stupak (D-Mich.) have relentlessly admonished the Food and Drug Administration for not fulfilling its regulatory mission.

Yesterday the lawmakers held a hearing that focused on the agency’s current inability to inspect imported drugs. The Wall Street Journal’s Corey Boles reports that the FDA’s Janet Woodcock thinks that $250 million would be enough money for the agency to inspect every foreign drug manufacturer. Dingell and Stupak propose $300 million. The current money allocated for foreign inspectors is $10 million.  Read Boles here. MB

Comment RSS - Trackback URI